What Do We Really Know About Intralymphatic Immunotherapy?
- 2 Downloads
Purpose of review
Allergen-specific immunotherapy (AIT) is the only causal treatment method of IgE-mediated allergies that may lead to long-term symptom amelioration even after the end of treatment, positively interfere with the course of disease, and improve the immunological situation of the patient. While AIT in general requires treatment periods over 3 up to 5 years, intralymphatic immunotherapy (ILIT) needs only three ultrasound-guided injections of low allergen doses into inguinal lymph nodes with 4-week time interval making the entire treatment possible within 2 months.
The number of published ILIT trials is continuously increasing and it has been mainly used for the indication of allergic rhinitis using commercially available grass pollen and birch extracts and Dermatophagoides farinae, Dermatophagoides pteronyssinus, dog or cat allergens, and moreover a recombinant MAT-Fel d 1 vaccine and autologous semen from a patient with post-orgasmic illness syndrome.
ILIT is a very promising AIT technique that could widely improve patient treatment However, there is not enough convincing evidence for a routine use of ILIT and no authorized commercial allergen extracts exist for this approach, so far. Dose-escalation studies and prospective DBPC efficacy trials need to be performed in diverse allergens like insect venom. Moreover, pediatric populations have not been present in former ILIT studies.
KeywordsIntralymphatic immunotherapy ILIT Allergen-specific immunotherapy AIT Allergic rhinitis
Compliance with ethical standards
Conflict of interest
Dr. Kündig reports grants from AlleCure Corp. USA, grants from ImVision AG, during the conduct of the study. In addition, Dr. Kündig has patents on intralymphatic immunotherapy where he is named as inventor. These patents, however, are owned by the University of Zurich. Dr. Klimek reports grants and personal fees from ALK-Abelló, Denmark; personal fees from MEDA, Sweden; grants and personal fees from Novartis, Switzerland; grants and personal fees from Allergopharma, Germany; grants and personal fees from Bionorica, Germany; personal fees from Boehringer Ingelheim, Germany; grants and personal fees from GSK, Great Britain; grants and personal fees from Lofarma, Italy; grants from Biomay, Austria; grants from HAL, Netherlands; grants from LETI, Spain; grants from Roxall, Germany; and grants from Bencard, Great Britain, outside the submitted work. Dr. Senti declares that she has no conflict of interest. Dr. Hoffmann declares that he has no conflict of interest.
Human and animal rights and informed consent
This article does contain studies with human subjects performed by GS, TK and HJH.
These studies have been performed according to the Declaration of Helsinki in its actual version and a positive vote of the responsible Ethical Committee was given before start of the study.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Pfaar O, Bachert C, Bufe A, Buhl R, Ebner C, Eng P, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int. 2014;23(8):282–319.CrossRefGoogle Scholar
- 8.Klimek L, Brehler R, Hamelmann E, Kopp M, Ring J, Treudler R, et al. Development of subcutaneous immunotherapy in over 100 years: from beginning to immunologically-oriented therapy concepts. Part 1: Immunological mechanisms, efficacy and indications. Allergo J Int. 2018 (in press).Google Scholar
- 9.Klimek L, Brehler R, Hamelmann E, Kopp M, Ring J, Treudler R, et al. Development of subcutaneous immunotherapy in over 100 years: from beginning to immunologically-oriented therapy concepts. Part 2: preventive aspects and innovations. Allergo J Int. 2018 (in press).Google Scholar
- 12.•• Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105(46):17908–12 This publication describes the first application of ILIT in men.CrossRefGoogle Scholar
- 17.• Schmid JM, Nezam H, Madsen HH, Schmitz A, Hoffmann HJ. Intralymphatic immunotherapy induces allergen specific plasmablasts and increases tolerance to skin prick testing in a pilot study. Clin Transl Allergy. 2016;6:19 This study provides new insights into possible immunological mechanisms of ILIT.CrossRefGoogle Scholar
- 24.Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position Paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). Allergo J Int. 2017;26(1):16–24.CrossRefGoogle Scholar
- 29.Malling HJ, Witten M, Poulsen LK. Reply: To J Allergy Clin Immunol. 2014;133(3):931–932.Google Scholar
- 31.Hellkvist L, Hjalmarsson E, Georen SK, Karlsson A, Lundkvist K, Winqvist O, et al. Intralymphatic immunotherapy with two concomitant allergens, birch and grass - a RDBPC trial. J Allergy Clin Immunol. 2018.Google Scholar
- 34.Mueller RS, Jensen-Jarolim E, Roth-Walter F, Marti E, Janda J, Seida AA, et al. Allergen immunotherapy in people, dogs, cats and horses - differences, similarities and research needs. Allergy. 2018.Google Scholar
- 40.Jonsdottir S, Svansson V, Stefansdottir SB, Schupbach G, Rhyner C, Marti E, et al. A preventive immunization approach against insect bite hypersensitivity: intralymphatic injection with recombinant allergens in alum or alum and monophosphoryl lipid A. Vet Immunol Immunopathol. 2016;172:14–20.CrossRefGoogle Scholar